DESTINY-Breast03 Phase 3 Study Results
Best change from baseline in sum of diameters, %
Change From Baseline in Target Lesions: OVC and RCC
Evaluable Populationa
80-
RCC renal cell carcinoma OVC = serous ovarian cancer
60-
40-
20-
-20-
OVC OVC RCC OVC OVC RCC OVC OVC OVC OVC OVC RCC OVC
0-
RCC OVC OVC RCC OVC RCC OVC
-40-
-60-
-80-
-100-
Starting dose level
1.6 mg/kg
13.2 mg/kg 4.8 mg/kg 6.4 mg/kg
18.0 mg/kg
19.6 mg/kg
100
80
60-
40-
20
0-
-20-
Change from baseline in sum of diameters
of target lesions, %
-40-
Daiichi-Sankyo
(1.6 mg/kg; N=1, n=1)
(4.8 mg/kg; N=6, n=4)
● (8.0 mg/kg; N=6, n=3)
(3.2 mg/kg; N=6, n=4)
(6.4 mg/kg; N=8, n=5)
(9.6 mg/kg; N=3, n=3)
-60-
-80
-100-
T
T
0
1
2
3
4
5
6
7
8
9
10
11
12
Time from first dose of study drug, months
Among 20 evaluable patients with measurable disease, there were 6 PRS (platinum-resistant OVC, n=5;
RCC, n=1)
4 confirmed PRs (platinum-resistant OVC, n=3; RCC, n=1)
2 unconfirmed PRs (1 patient still in the trial)
12 patients had stable disease
Data cutoff: February 25, 2022.
OVC, ovarian cancer; PR, partial response; RCC, renal cell carcinoma.
a Patients who received ≥1 dose of study treatment and have completed ≥1 postbaseline tumor assessment or discontinued treatment for any reason.
ASCO 2022 #3002 Oral
104View entire presentation